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Abstract 
The goal of this project was to analyze the feasibility of commercializing a newly 
patented ergonomic surgical scalpel. In order to achieve this, we collected data, 
performed a feasibility analysis, and provided recommendations. We evaluated four 
areas: the medical device market, manufacturing, consumer research, and intellectual 
property. We concluded that this product would not be viable for commercialization as a 
stand-alone product. Alternative methods to commercialization may be required in order 
to generate future success if this product reaches market.   
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Executive Summary  
Professionals in surgical fields often require high-quality surgical tools for increased 
precision and comfort. With the constant improvement of surgical devices, the use of 
ergonomically-efficient tools is becoming more common. The sponsor for our project was Dr. 
Raymond Dunn, Professor and Chief of Plastic Surgery at UMass Memorial Medical Center. His 
company, 5G Medical, was formed in 2011 and currently holds multiple patents in the medical 
device industry. Dr. Dunn aims to identify the ideal method for commercializing each of the 
patents. One of these patents is for recently designed surgical scalpel that features an ergonomic 
handle. He developed this scalpel because the scalpel that is currently used has some perceived 
design limitations.  
Goal and Methodology  
 Our project goal was to analyze if it was feasible to commercialize the 5G ergonomic 
scalpel. In order to achieve this goal, three objectives needed to be accomplished. The first 
objective was data collection. Background research was the first step in the data collection 
process. Afterwards, our team interviewed industry experts, manufacturers, users of the existing 
scalpel, and hospital staff. This allowed us to gain a better understanding of the aspects that 
needed to be considered in order to make an informed decision. After the data collection portion 
of the project had been completed, we performed a feasibility analysis to determine whether 
commercializing the scalpel was possible. This involved constructing a cost-benefit analysis 
based on all the information we had previously gathered. We identified four main aspects that 
impacted the commercialization of the 5G ergonomic scalpel: intellectual property, 
manufacturing, consumer research, and current state of the market. After having reached a 
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conclusion, our final task was to provide 5G Medical with recommendations on how to move 
forward in the market. 
Results 
After having researched each of the four main aspects, we could then proceed to interpret 
the results. For intellectual property, we assessed whether the protection and freedom to operate 
offered  by  5G’s  patent  would  significantly  help  this  product  succeed  in  the  market.  Our team 
determined that  5G’s  ergonomic  scalpel  patent is of marginal strength. Due to the limited 
protection and freedom to operate provided by the patent, a more conservative marketing scheme 
must be implemented in to order to reduce the heightened risk of substitute or imitation products. 
Thus, this conservative marketing scheme entails directing the marketing focus away from a 
more generalized market, and towards specialty or niche markets. 
For the manufacturing aspect of our research, we needed to determine whether it was 
possible  to  create  the  ergonomic  scalpel  to  5G’s specifications; and, if this was financially viable. 
From our visit to Nypro, a plastics manufacturing company, we decided that the feasibility of 
manufacturing this product was marginal. This was mainly due to the cost of the raw materials 
involved in the manufacturing  process,  and  the  design  complexity  of  the  scalpel’s  handle.  We  
also  had  to  take  into  account  the  possible  distribution  methods  for  5G’s  scalpel,  and  the  
complications caused by the need to sterilize this product. 
 During the consumer research portion of our project, we aimed to determine how the 
surgeons perceived the benefits of the prototype; this would help us establish whether there was 
a need for the product. Overall, we learned that surgeons found almost no issues with the current 
scalpel. For the 5G prototype, surgeons saw the ease in making circular incisions as its only 
benefit; however, they did mention several disadvantages. In summary, they did not see a reason 
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to switch to a new scalpel unless that scalpel had all the benefits of the traditional scalpel as well 
as all the benefits of the prototype. 
In respect to the current state of the market, our team determined that there is no present 
need for this new product. The industry has exhibited recent and continued success as a whole. 
Success was generated despite employing the same basic scalpel design for the past several 
decades. Because of this, we determined the need for a new product to be marginal. 
Assessment and Recommendations 
 Based on our determination that each of the previous four aspects were of marginal 
impact, we concluded that, as of now, the 5G ergonomic scalpel is not a viable option for 
commercialization as a stand-alone product. However, we do not believe that the product 
concept should be entirely abandoned. We identified alternative methods of commercialization 
that may be employed in order to generate future success if this product reaches market. These 
recommendations are to consider: targeting the hobbyist market, licensing the product to an 
existing company, developing and launching a family of ergonomic surgical tools, and analyzing 
any further possibilities. 
  
 
    
  
  
   
1 Introduction 
In the medical industry, quality patient care is the ultimate goal. Surgeries, known for 
their precision and intricate detail, require highly-skilled medical professionals and high-quality 
surgical tools. The more assured a surgeon feels when using his/her surgical tools in the 
operating room, the more confidence they will have in the procedure, and the smoother it will 
run. With the constant improvement of surgical devices, ergonomically efficient tools are on the 
rise, providing the best possible comfort and outcome from surgery. A surgical scalpel is a 
common medical tool utilized in all invasive surgical procedures, and will be the focus of this 
project. 
 Dr. Raymond Dunn, Professor and Chief of Plastic Surgery at UMass Memorial Medical 
Center, is a practicing plastic surgeon, with the vast majority of his work consisting of 
reconstructive surgery. In early 2011, Dr. Dunn formed the company 5G Medical, with the goal 
to improve lives using advanced technology in surgery and wound care. He currently holds over 
ten patents, primarily in the medical device field. 5G Medical focuses on managing these patents, 
and would like to determine the optimal method of commercialization for each individual patent. 
One of the devices specified by these patents is a new surgical scalpel that features an ergonomic 
handle. 
The purpose of this project is to analyze the feasibility of commercialization for the 
newly patented 5G ergonomic scalpel. In order to perform a feasibility analysis, our team will 
make multiple assessments in order to reach a conclusion as to whether this tool will generate 
success when put on the market. A portion of this assessment will include providing a cost-
benefit analysis in order to determine if the benefits of this device outweigh its costs. In addition, 
we will need to assess the risks associated with launching this new tool. An exhaustive market 
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assessment will also be conducted in order to identify potential competitors, as well as ascertain 
the ergonomic  scalpel’s  room to operate within the surgical tool market. Lastly, we will need to 
determine the strength of the intellectual property (IP), and identify similar IP, which could pose 
a potential threat to the success of the ergonomic scalpel.  
Launching a new product is difficult without gathering the information necessary to help 
it expand and create value in the market. Ultimately, 5G Medical currently lacks this 
commercialization information, which inhibits their ability to advance into the medical device 
market. By providing analysis and assessing the feasibility of commercializing the ergonomic 
scalpel, our team aims to provide 5G Medical with recommendations for the optimal method of 
bringing this design to market.  
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2 Background 
2.1 History of the Scalpel   
The word surgery comes from the Greek kheir, meaning hand, and ourgos, meaning 
work. In Latin, it is called chir-urgia,  meaning  “handwork”  (Kirkup,  2006).  It  references  the  
most  important  elements  of  all  surgical  procedures,  the  surgeon’s  hands  and  the  surgeon’s  skill.  
The relevance of this point is such that a distinction has been made between natural and artificial 
surgical instruments. The natural instruments definition refers to the parts of the human body 
directly used in a surgical procedure, while the artificial instruments are the man-made tools that 
assist the former (Kirkup, 2006). 
The most essential artificial tool for any surgeon is the surgical scalpel; it is ubiquitous to 
any surgical tray, since it is used in virtually all invasive procedures. A scalpel is a small, sharp-
bladed instrument used for surgery and dissection. Scalpels are an essential component in all 
surgeons’  toolboxes,  and  are  the  most  commonly  utilized  device  by  surgeons  today.  Surgical  
scalpels consist of a blade and a handle.  
The handle is also known as a "B.P. handle", named after Charles Russell Bard and 
Morgan Parker, founders of the Bard-Parker Company. Parker patented the 2-piece scalpel 
design in 1915 and the Bard-Parker Company developed a method of cold sterilization that 
would not dull the blades, contrary to the heat-based method that was previously used (Ochsner, 
2009). Medical scalpel blades are manufactured with a corresponding fitment size so that they fit 
on only one size handle. 
Scalpels may be either disposable or re-usable. Re-usable scalpels can have attached 
blades or non-attached, replaceable blades. Disposable scalpels typically have a plastic handle 
and are used only once. Scalpel blades are individually packed in either sterile or non-sterile 
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pouches, with sterile pouches being the more common of the two. The most commonly utilized 
blades are those made of hardened and tempered steel, stainless steel, or high carbon steel. 
However, titanium, ceramic, diamond, and even obsidian blades are in the market. 
The surgical field has substantially improved due to our enhanced anatomical knowledge, 
the establishment of the germ theory of disease, and the discovery of anesthesia, blood 
transfusion, and antibiotics. Due to these, and many more, advancements, surgeons today have 
many tools at their disposal that were not previously available. 
The earliest medical tools were made of wood, bone, antlers, shells, or stone, dating back 
as long as 1 million years ago. The knife was the first tool to be developed, and it still maintains 
its status as the most commonly used tool to date. The discovery of copper smelting in the year 
3500 B.C.E. accelerated the innovations in the surgical field.  Bronze weapons and tools, such as 
those shown in Figure 1 below, overwhelmingly dominated any other materials for at least two 
thousand years (Ochsner, 2009). 
 
Figure 1: Bronze knives found in the destruction of Pompeii (Oschner, 2009) 
 
Knives dating to 3000 B.C.E. are believed to have been used for surgery. Around the year 
1200 B.C.E., iron had replaced bronze tools entirely. A mix of bronze and iron scalpels have 
been found in Peruvian, Greek, and Roman settlements that flourished nearly 2,000 years ago 
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(Ochsner, 2009). However, surgical procedures remained virtually the same throughout the dark 
ages. Possibly the largest advancement in  this  field  came  in  the  1800’s;; Louis  Pasteur’s  
revolutionary advancements in sterilization of medical devices greatly enhanced the safety and 
success of medical procedures. By those times, steel had become commonplace due to the 
introduction of the blast furnace.  
The medical device market as a whole has experienced positive growth regardless of the 
absence of innovation on the scalpel industry. This rate of growth seen over the past several 
years is anticipated to be sustainable for years to come. This projected sustained growth is due to 
a plethora of factors, including average age of population and public spending on healthcare, that 
positively impact the medical supply manufacturing segment of the market. This market has 
experienced over two percent growth each of the past two years, and three out of the past four, 
with an industry total of over $89 billion in revenues last year (Sonn, 2013). 
One of the primary key external drivers of this market is the number of adults over 65 
years of age. This is a vital demographic to the overall performance of the medical and surgical 
device industry because there is a strong positive correlation between the number of adults over 
the age of 65 and the demand for surgeries, meaning that the larger this demographic is the 
Figure 2: Number of Adults Over 65 Years Old (Sonn, 2013) 
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greater the demand for surgeries. The number of adults over the age of 65 has increased over the 
past  decade;;  however,  since  the  “baby-boomers”  are  nearing  this  65  year-old threshold, this 
growth is only anticipated to continue in the near future (see Figure 2) (Sonn, 2013). Another 
demographic driving demand for the medical and surgical devices, by requiring a heightened 
number of physicians visits and surgeries, is the obese and overweight demographic. Currently, 
over half of the U.S. population is overweight, with over a third of the population being 
considered obese, a number that has increased consistently over the past decade (Centers for 
Disease Control and Prevention, 2013). A 2009 government study shows that the average obese 
individual‘s  medical  costs  are  $1,429  more  than  a  normal  weight  individual,  and  an  estimated  
$147 billion in total medical cost of obesity in the US in 2008 (Centers for Disease Control and 
Prevention, 2013).  
An additional key external driver of the medical device manufacturing market is total 
healthcare expenditures. Government funding for Medicare and Medicaid, as well as the amount 
of consumers with private healthcare coverage, comprise this statistic. Federal funding for 
Figure 3: Federal Funding for Medicare and 
Medicaid (Sonn, 2013) 
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healthcare coverage is a vital statistic because it directly affects how much patients must pay for 
industry products, and how much operators will receive in payments from Medicare. Since this 
funding has increased under the Obama administration, and anticipated to continue growing, 
more people can afford surgeries, thus positively benefiting the surgical device market through 
increased demand of surgeries. Similarly, private healthcare coverage provides insured patients 
with a more diverse choice of doctors, due to increased ability to pay for healthcare services. 
However, private healthcare coverage accounts for over half the revenue generated by specialist 
doctors, a demographic which is largely made up of surgeons. Therefore, as the number of 
people with private health insurance escalates, the amount of surgeries performed increases, 
fueling increased demand for medical supplies and equipment. Thus, it is a positive indication 
for the medical and surgical device market because the amount of people with private healthcare 
Figure 4: Total Health Expenditure 
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has increased over the past several years, and is anticipated to increase gradually over the course 
of 2013 (Sonn, A. 2013) (MarketLine, 2011). 
These key external drivers have a direct impact on the amount of physician visits per 
year. As one might expect, the number of physician visits per year correlates very closely to 
amount of surgeries performed, and thus the demand for surgical devices. Each of these external 
Figure 5: Industry Revenue (Sonn, 2013) 
Figure 6: Number of Physician Visits (Sonn, 2013) 
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drivers increases the amount of physician visits per year, a 2.6% increase last year, consequently 
benefitting the surgical device market. Therefore, since the number of physician visits is 
anticipated to increase by an estimated 4.8% in 2014, the revenue for the medical device market 
is projected to grow by a substantial 5.1% margin (Sonn, 2013). Furthermore, this growth is 
likely sustainable in the years to come because the demand for medical and surgical devices is 
extraordinarily inelastic. Meaning that, unlike many other products, the demand for medical and 
surgical devices is relatively immune to the current state of the economy; this is because people 
need healthcare regardless of economical state. This claim is verified by a 9.7% and 10.3% 
growth in revenues for the surgical device market over the course of 2007 and 2008. The 
external drivers previously discussed, coupled the inherent inelastic demand for the medical 
device market, suggest promising sustainable growth for this industry beyond just the estimated 
5.1% revenue growth in 2014. These positive driving factors for this industry result in projected 
growth of over 3% each of the next five years.  
 
 
Figure 4: Annual Change (Sonn, 2013) 
Although, as a whole, the medical device industry is prospering, with anticipated growth 
in the foreseeable future, there are several factors hindering it from achieving heightened growth 
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and success. Quite possibly the largest threat to this industry is the 2.3% excise tax levied on all 
medical devices by a manufacturer, producer, or exporter. The medical device excise tax was one 
of the key provisions put in place by the 2010 healthcare reform legislation, and was put into 
effect on January 1, 2013. This tax applies to all manufacturers of medical device, regardless of 
size or revenue, and is anticipated to have a substantial negative impact on some of the smaller 
players in the medical device industry. This excise tax is projected to cost the medical device 
industry over $20 billion in the next ten years, hurting the bottom  line  of  many  companies’  
profits. The negative impact of this tax could extend further beyond just the small companies in 
the industry, as this tax could influence companies of all sizes to reduce funding for research and 
development operations, as well as workforce reductions through either lay-offs or outsourcing 
of manufacturing operations to lower-cost locations. Additionally, this tax could inhibit 
innovation  for  medical  technology  because  the  costs  of  the  excise  tax  might  impede  investors’  
willingness to fund start-up companies and commercialization of new technology. However, 
stakeholders in the medical device industry could rest easier knowing that on March 21, 2013 the 
U.S. Senate voted to repeal the medical device excise tax. Although a final verdict has not been 
 
Figure 5: Products and Services (Sonn, 2013) 
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made,  the  voting  results  evinced  the  industry’s  lobbying  clout,  who  had  been  lobbying  to  repeal 
this tax ever since its onset (Sonn, 2013). 
 Now that the macroeconomic characteristics and factors of the medical device industry 
have been thoroughly elucidated, the next aspect to consider is the various segments within this 
industry. The total industry revenue for 2013 is $91.7 billion, this annual revenue is dispersed 
among eight sub-sets that comprise the medical device industry (in order of largest to smallest 
revenues);;  orthopedic  instruments,  surgical  instruments,  diagnostic  apparatus,  catheters,  “other”,  
syringes and hypodermic needles, blood transfusion and IV equipment, and internal fixation 
devices. Revenue generated from orthopedic instruments comprises about 23% of the total 
revenue in the medical device industry, with surgical devices being the second largest segment 
with about 19% of total industry revenue. Orthopedic instruments are utilized in surgeries 
concerning conditions involving the musculoskeletal system. These are the most vital sub-sets in 
the medical device industry to this project because both require the production on surgical 
devices (Sonn, 2013) (MarketLine, 2011). 
 In 2011, these combined subsets, hereby referred to as the surgical device market, 
generated roughly $40.6 billion in total annual revenues. This surgical device subset can be 
Figure 6: Products and Services (Kaczanowska, 2011) 
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broken down further into four additional market segments (in order of largest to smallest 
revenues); general surgical instruments, specialized surgical instruments, electrosurgery 
instruments, and instrument servicing. The vast majority of the total revenue is generated by the 
general surgical instruments subset, producing about 62% of the total industry revenue. The 
segment of general surgical instruments is comprised of basic instruments necessary to perform 
all types of surgeries, such as; scissors, scalpels, retractors, needles, clamps, and forceps. These 
products can be either reusable or disposable, although the current industry trend is towards more 
reusable equipment in order to reduce cost and minimize waste  (Kaczanowska, 2011). 
The following section focuses on how technology in the surgical field has changed at a 
rapid pace, and why this rate of change is possible. There is a noticeable difference before and 
after the year 1980; this is due to the introduction of the Bayh-Dole Act. 
 
2.2 Bayh-Dole Act of 1980 
Technology transfer is the relocation of research conclusions from universities to the 
public market. The overwhelming success of the Manhattan Project served as a catalyst for 
increasing university research in the United States. Due to the growing acceptance of such a 
change, the Office of Naval Research and the National Science Foundation were created in the 
years 1946 and 1950, respectively. The movement also helped increase federal funding for the 
National Institutes of Health. 
By  the  1960’s  and  1970’s,  concerns  arose  regarding  the  introduction of new technologies 
into the public market. The rate at which technologies were being commercialized was woefully 
low, due largely to the lack of a standardized policy regarding authorship of federally-funded 
inventions. In 1980, for example, fewer than five percent of the 28,000 government-owned 
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patents were licensed or commercialized (Stevens, 2004). The patents that were commercialized 
had to go through an arduous waiver process prior to commercialization. Even then, the licensee 
would not have exclusive manufacturing rights, dissuading companies from investing in the new 
technologies in the first place - after  witnessing  a  firm’s  success,  competitors  could  just  copy  its  
marketing and business plan strategy. 
 In his introductory statement on September 13, 1978, Senator Birch Bayh said, "Unless 
private industry has the protection of some exclusive use under patent or license agreements, 
they cannot afford the risk of commercialization expenditures.  As a result, many new 
developments  resulting  from  government  research  are  left  idle”  (Stevens,  2004,  page  95).  
Evidently, industry leaders were not being attracted to government-owned patents. Taxpayers 
were obviously not benefitting from the almost non-existent commercialization of new 
innovations.  
In order to counteract this persisting problem, the Bayh-Dole Act was passed on 
December 12 of 1980. It affects the ownership of inventions that were achieved through federal 
funding. The act allows universities, small businesses, and nonprofits to own the rights to an 
invention even if its development was federally funded. Whereas before, authorship of 
inventions arising from federally funded contracts or grants had to be assigned to the federal 
government. The possibility of having exclusivity rights served as an incentive for universities to 
participate in the commercialization process, leading to more innovations entering the market. 
Since the law was enacted in December of 1980, over 5,000 companies have been built around 
university research (Goldfarb & Henrekson, 2003). Figure 10 below illustrates the percentage of 
patents that were granted to U.S. research universities during the last half of the 20th century. 
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Figure 7:  Percentage of US Patents Granted to Research Universities (Goldfarb & Henrekson) 
 
 It  is  important  to  note  that  the  graph’s  y  axis  is  in  terms  of  percentages,  indicating  a  
significant change in the number of patents that were commercialized after the Bayh-Dole Act 
was introduced. As foreseen, the licensing of new technologies from universities to private 
industries greatly stimulated the U.S. economy. One example of this is the biotechnology 
industry: an industry that was created, and is being shaped, by university research. 
Not all of the opinions surrounding the Bayh-Dole enactment debate were supportive. 
The opposition suggested that exclusivity would lead to monopolization and the raising of prices 
- they were doubtful about whether or not taxpayers would benefit equitably. Additionally, there 
was some concern about foreign industries unjustly profiting from the newly published 
knowledge and innovations. 
In  the  United  States,  the  university  environment’s  competitive  nature  has  encouraged  
educational institutions to facilitate the continued involvement of academic researchers. This 
active involvement is necessary because potentially innovative ideas typically reach technology 
licensing officers while still in a very primitive stage. Understandably, the majority of the 
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essential knowledge is implicit only to the researcher. Surprisingly, assigning authorship to 
universities or other research institutions has proven to be a better incentive for individual 
researchers than awarding the ownership rights to the researchers themselves. The activities 
required for academic research and the ones required when developing a commercialization plan 
are not similar - researchers are dissuaded from pursuing the latter. This is because prestige, and 
higher income, in the academic field can be associated with the number of reputable research 
publications. However, if the university can provide incentives for inventors to commercialize 
their innovations, the inventors will reap both academic and monetary benefits.  
The Bayh-Dole Act has therefore had more beneficial consequences than initially 
anticipated. It has stimulated the creation of numerous technology transfer departments at many 
universities. Additionally, it has allowed individual researchers to strive for the 
commercialization of their inventions, without undertaking the entire costs and risks themselves. 
These departments usually cover a portion of the cost and also provide valuable resources and 
activities that the inventor could not pursue individually.  
 
2.3 Use and Disposal Research 
In the late 1970s, a formerly single-use medical device started to become reused by their 
operators. Reusable medical devices became a more common practice in order to save money for 
hospitals and other  institutions.  “Approximately  20  to  30%  of  U.S.  hospitals  reported  that  they  
reuse at least one type of single-use  device” (CDC, 2009). Over the past two decades, there has 
been general controversy due to regulatory, medical, ethical, legal, and economic issues 
surrounding this practice.  
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In most hospitals, surgeons use both reusable and disposable tools. Reusable tools are used 
over and over again until they show signs of weathering or are no longer able to fulfill surgical 
needs. They are sterilized after every use. For example, in a reusable scalpel, the blade is 
disposed of after usage, meanwhile the handle gets sterilized and reused for years. On the other 
hand, disposable tools are used once and disposed of after every surgery. When a disposable 
scalpel is being used, both the blade and handle get disposed of after surgery. Reusable scalpels 
are used during most surgeries; however, disposable scalpels can also be used for convenience 
purposes.  
Because reusable tools are preferred to disposable ones, there have been additional 
precautions taken to ensure the safety of their use. People have become concerned by the risk of 
infections and injuries that could  occur  when  these  medical  devices  are  reused.  “In  August  2000,  
FDA released a guidance document on single-use devices reprocessed by third parties or 
hospitals” (CDC, 2009). It states;;  “Hospitals or third-party repressors will be considered 
manufacturers and  regulated”  in  the  same  way.  A single-use device, with intentions for reuse, 
must adhere to these same regulatory requirements. In August of 2000, the FDA intended to 
enforce premarket submission requirements in the case of class I devices within 18 months.  
 
2.4 Sterilization within Healthcare  
The sterilization of medical equipment is a crucial aspect in all healthcare facilities. 
Sterilization processes are required to ensure disinfection and the prevention of diseases. The 
surgical ergonomic scalpel that we will be working with will be evaluated for both reusable and 
one-time use material. This analysis will enable us to determine which option would prove more 
cost effective and plausible. As is the case with all reusable medical tools, this scalpel will need 
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to abide by strict sterilization guidelines in order to gain a positive reputation in making sure the 
patients’  safety  comes  first. By identifying how much it will cost to sterilize the proposed 
prototype, we will be able to see how cost effective the reusability of the scalpel is. 
In general, a tool is sterilized in order to kill potential bacteria, microorganisms, and 
fluids that may reside on its surface. Transmitting harmful microorganisms is a major concern, 
especially during surgeries lacking a proper sterilization process. This concern makes the need 
for sterilization of any medical tool essential, particularly surgical scalpels. 
The materials that comprise the tools are a vital aspect of the sterilization process. 
Picking the right material to use, when manufacturing the scalpel handle, is difficult because it 
can have a substantial impact on the commercialization process. The material selected to 
manufacture the scalpel will likely undergo high heat treatment and therefore will need to be 
resistant to high temperatures. 
Most surgical devices, such as scalpels, are considered critical items that require 
sterilization in order to prevent disease transmission and microbial contamination. The most 
common form of sterilization for these instruments is steam sterilization (CDC, 2009). 
 
2.4.1 Steam Sterilization  
As mentioned above, surgical tools predominantly undergo steam sterilization because of 
its  wide  use  and  dependability.  Steam  sterilization  is  described  as  “moist  heat  in  the  form  of  
saturated  steam  under  pressure…  [And]  is  nontoxic,  inexpensive,  rapidly  microbicidal,  
sporicidal,  and  rapidly  heats  and  penetrates  fabrics”  (CDC,  2009). Moist heat is a vital 
component in the sterilization process because it eliminates all microorganisms by making 
enzymes and structural proteins unsuitable to thrive. 
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All sterilization takes place in an autoclave; an enclosed container used for chemical 
reactions (CDC, 2009). The tool that is in the process of being sterilized needs to be directly 
exposed to the steam for a specified period of time, at the ideal temperature and the correct 
pressure.   The most effective parameters for sterilization within an autoclave are; thirty minutes 
at 250 degrees Fahrenheit, and then four minutes at 270 degrees Fahrenheit. In addition to 
exposing the device to the correct temperatures, the steam in the autoclave should have a dryness 
fraction of greater than or equal to 97 percent (CDC, 2009). 
Instruments that are going to be put into an autoclave must be placed either individually 
or in sets, as well as covered in some sort of pouch. Additionally, a sterilization indicator is 
required to help identify which instruments have been sterilized, and which have not. This is 
determined by either putting an autoclave indicator strip on the device, or tape on to the pouch 
containing the instrument (Penn State, 2013).  
        Each day a Bowie-Dick test is performed before the first load of sterilization, in order to 
ensure that the autoclaves are running properly. This test is important to inform the sterilizer of 
any mishaps with the machine, such as air leaks or inadequate air removal (CDC, 2009). Any 
issues detected must be fixed right away, prior to continuing the sterilization process. 
Understanding  how  the  sterilization  process  influences  the  performance  of  5G’s  ergonomic  
scalpel will allow the team to accurately compare the product to those of the competition. The 
following section discusses the existing competition in the surgical device manufacturing 
industry. 
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2.5 Industry Competition 
Currently, there is a lot of internal competition within the surgical tool manufacturing 
industry, and this trend is expected to remain the same for the foreseeable future. Technological 
advances have made the manufacture of high-end medical devices easier, effectively reducing 
barriers to entry, such as specialization. Hence, the industry is riddled with a vast amount of 
players. This is a recent change, as competition used to be minimal within this industry. 
Technological competence, design excellence, high product performance, service quality, and 
pricing, are some of the factors affecting the level of competition in this industry. Price 
competition, in particular, is expected to become more of a factor in the few next years 
(Marketline, 2011). On the other hand, there is not much competition from external sources 
because surgeons need to use instruments that have been approved by certain entities after 
passing through regulations. 
Covidien PLC is the only major player in the surgical device manufacturing industry, 
with  5.9%  of  the  market  share.  Some  of  the  company’s  best-known brand names are ForceTriad, 
LigaSure, and V-Loc. The remaining portion of the market share is divided amongst numerous 
smaller  firms.  Covidien’s  headquarters  are  located  in  Ireland.  The  company  supplies  hospitals  
worldwide, but the majority of its sales is to hospitals located in the United States – 
approximately 55%. After Tyco International separated into three distinct companies, Covidien 
became the head of the former Tyco healthcare branch. Covidien employs over 40,000 people, 
and has made purchased several smaller companies within the last five years, the largest being 
ev3  Inc.  for  $2.5  billion.  Covidien’s  revenue  within  the  United  States  was  $2.4  billion  in  2011,  
indicating a growth rate of 8.9% from 2006, when they gained $1.6 billion in U.S. revenues 
(Kaczanowska, 2011). 
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 Another industry that significantly overlaps with the surgical device manufacturing 
industry is that of medical instrument and supply manufacturing. Johnson & Johnson is the 
biggest player within it, with 14.3% of the market share and operating in over 60 countries. The 
company develops, manufactures, and markets pharmaceutical products and medical devices. 
These include surgical tools, orthopedic and cardiovascular care products, as well as monitoring 
devices. This product segment contributes  to  approximately  40%  of  the  company’s  revenue.  Out  
of its 146 manufacturing facilities, 51 are located within the United States (Sonn, 2013).  
 Baxter International is another significant player in the medical instrument and supply 
manufacturing industry. Its estimated market share is 4.1%. Incorporated in 1931, the company 
has recently created a medical products department. Overall, it employs approximately 50,000 
people, manufacturing its products in over 27 countries. However, over 60% of its sales are 
outside of the United States (Sonn, 2013). The company ran into some major problems when one 
of its products, the COLLEAGUE Infusion Pumps, was forced to be recalled as ordered by the 
U.S. Food and Drug Administration (Baxter U.S.). 
Boston Scientific Corporation owns about 4.0% of the market share. Like Johnson & 
Johnson, Boston Scientific develops, manufactures, and markets medical devices. The company 
has 12 manufacturing plants, employs approximately 24,000 people, and sells to over 40 
countries.  Around  half  of  the  company’s  revenue  stems  from  its  United  States  operations  (Sonn, 
2013).  Some  of  the  issues  they  faced  were  due  to  the  company’s  inability  to  match  other  
companies’  product  development  and  release  speed. 
 Becton Dickinson and Company completes  the  list  of  the  industry’s  major  players.  
Becton Dickinson controls approximately 3.7% of the market share. Over 50 countries purchase 
the  medical  devices  and  instrument  systems  developed  and  manufactured  by  the  company’s  
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30,000 employees. Its main customers are healthcare institutions, research institutions, 
laboratories, and patients (Sonn, 2013). 
 
2.6 Pricing  
A major barrier to entry in the market for the ergonomic scalpel handle is physician 
adoption, even though reaching organizations and policies always play a vital role in buying 
decisions for hospitals and clinics. If the pricing is competitive or below current offerings, this 
will eliminate one barrier to entry, but overcoming physician adoption is still a problem facing 
5G and its success going forward with the marketing of the scalpel handle. Depending on global 
location, the scalpel handles will be purchased by institutions directly from manufacturers or 
through distribution channels. 
One competitor to the prototype ergonomic scalpel is the Canica Standard Scalpel by 
Canica Design Inc., which is reusable, stainless, and priced at $100. This scalpel is supplied in a 
non-sterile condition. Additionally, the Siegel knife handle by INTEGRA Milex is reusable and 
stainless and priced at $50. The BD Surgical Blade handle (371050,371060 and 371080) by 
Aspen Surgical Products, Inc., is of disposable, plastic, and priced at $15- $25 (5G Medical, 
2011). Although looking at the competition is important for deciding the pricing of the proposed 
prototype, it is also important to look at the rules and regulations that control the scalpel 
manufacturing industry. The FDA sets the standards that surgical instruments must meet, and 
changes in these standards could affect the production and pricing of the proposed prototype. 
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2.7 FDA 
A surgical scalpel is  classified  as  a  “manual  surgical instrument for general use and is a non-
powered, hand-held, or hand-manipulated device, either reusable or disposable, intended to be 
used in various general surgical procedures” (FDA, 2013). 
Initially, there were regulations published for medical devices in 1976. They called for 
“establishment registration and device listing information to be submitted to the Center for 
Devices and Radiological Health (CDRH) on several paper forms: FDA 2891, Registration of 
Device Establishment; FDA 2891a, Annual Registration of Device Establishment; and FDA 
2892,  Device  Listing” (FDA, 2013). Some amendments recently in the past years are worth 
noting in the case of a company involved with medical devices.  “In October 2002, section 207 of 
MDUFMA further amended section 510 of the FD&C Act by extending the requirement for 
electronic submission of registration information to include domestic firms as well as foreign 
firms” (FDA, 2013). 
Before a product goes to market, the FDA uses two types of requirements for nonexempt 
class I and II devices; a 510(k) submission and a premarket approval application. The 510(k) 
submission may have to show that the device is as safe and effective as the same device when 
new (CDC, 2009). It has to show scientific evidence that the device is safe and effective for 
whatever its intended  use  may  be.  The  FDA’s  has  a  1-year leeway with allowing hospitals to 
comply with the non-premarket requirements (registration and listing, reporting adverse events 
associated with medical devices, quality system regulations, and proper labeling) (CDC, 2009). 
Hospitals have the option to stop reprocessing single-use devices, comply with the rule, or 
outsource to a third-party re-processor.  
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2.8 Ergonomics 
“Ergonomics  [is]  the  study  of  the  engineering  aspects  of  the  relationship  between  workers  
and  their  working  environment”  (Daintith, pg 197, 2010). By using ergonomics, 
engineers are able to create better interactions between humans and their tools. 
Ergonomics takes into account both the physical and psychological needs of the user. 
These needs are taken into account in order to generate the optimal physical fit comfort, 
while also knowing how to use the device to its maximum capabilities. Some examples of 
how various studies overlap and are affected by human factors, which must be addressed 
by ergonomics in order to develop a safe and effective system, are listed below. 
x Psychology and engineering overlap to create operations research  
x Physiology and engineering overlap to affect industrial hygiene 
x Industrial design and psychology overlap to affect product semantics (Kutz, 
1998). 
There are a plethora of issues that may arise in this process that can make user interface 
increasingly difficult. The list below illustrates the several common issues as well as how any 
particular issue can affect the user interface.  
x The  user’s  ability  to  use  a  product  is  affected by the tool, the work station, the 
environment, and the task.  
x The task (job content) is affected by application, new technology, training, 
support systems, and many other things. 
x The work station and environment are affected by biomechanics, anthropometrics, 
lighting, climate, work surfaces, and many other things.  
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x The user is affected by anthropometrics, physical and psychological needs, 
training/experience, and capability (Kutz, 1998). 
Ergonomics helps eliminate the stress and strain of the human body by making it easier for 
people to use, and even understand, the devices involved.   
 
2.9 Uniqueness of Proposed Prototype 
The proposed scalpel prototype is different from other surgical scalpels because of claims 
made in the patent of the 5G scalpel. The filing had been rejected several times before finally 
being accepted by the examiner. Many of the claims were rejected because they were too similar 
to other patents. The examiner worked with Dr. Dunn to fix the claims. All of the edits to the 
filing are contained in the file wrapper in the appendix. An example of the rejections is shown in 
Figure 11. 
 Figure 8: Patient Claims (Claim Rejection – 35 USC 103) 
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Eventually, the filing was accepted with the claims listed in the appendix - setting it apart 
from all other prior art. A large portion of the claims are based on the first claim, which was 
originally rejected but has since been revised and accepted by the same patent reviewer, a good 
sign regarding the strength of the patent. According to the claims, the prototype will be used 
differently from traditional scalpels since it is made so surgeons only have to turn their wrists 
instead of their whole arm when cutting during surgery, theoretically enhancing the ease and 
safety of performing invasive surgery. The prototype is comprised of different material than most 
traditional scalpels; the proposed prototype has a plastic homopolymer (specific type not 
specified) handle, while traditional scalpels are made of steel.   
 
2.10 Summary  
In the background, we have discussed the history of the scalpel, as well as the current state 
of the medical and surgical device industry as a whole. We proceed to discuss the specific 
competitors in the surgical device market, pertinent laws and regulations, and other vital 
information pertaining to scalpels in particular. Additionally, we elucidate how the proposed 
prototype, that 5G Medical is developing, is different from traditional scalpels currently in use 
today. This new ergonomic scalpel will allow surgeons and manufacturers to purchase a different 
type of tool that will provide additional comfort and operational flexibility when performing 
surgeries. The design allows the user to hold the handle at any angle with a greater degree of 
precision. Consequently, the ergonomic scalpel can be easily rotated with minimal body position 
adjustment. Based on our background research it is not clear yet whether there is a strong need 
for a new ergonomic scalpel; however, Dr. Dunn provides many insightful reasons as to how it 
will benefit the industry. Although the surgical device industry is growing independently of the 
 
 
 35 
ergonomic scalpel, this leaves room for a new device that could fill a need that surgeons have not 
yet recognized. In the next section, Methodology, we will discuss how we plan to gather 
information and insight in order to determine the feasibility of bringing the proposed prototype to 
market.  
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3 Methodology 
The goal of this project is to provide an analysis of the potential commercialization of the 
5G medical ergonomic scalpel prototype. It is crucial to accurately analyze and interpret the 
feasibility in order to determine the potential for success presented by this new product.  
There are certain objectives that we will need to meet in order to accomplish our goals:  
- Data collection 
- Feasibility analysis 
- Provide recommendations 
Data collection was necessary to gain first-hand opinions from industry experts, users of the 
existing device, manufacturers, and other hospital staff. The data gathered was analyzed in order 
to aid us in providing a feasibility analysis. In order to help us gather the information we need, 
we met with personnel from the consumer and manufacturing end of the supply chain, as well as 
conducted extensive background research. After gathering the necessary information, we were 
able to perform a feasibility analysis to determine the viability of commercializing 5G’s  
ergonomic scalpel. Our final objective is to provide 5G Medical with recommendations of, what 
we believe to be, the best method for bringing the scalpel to market, if at all. An analysis of the 
current  market  and  industry’s  performance  is required, as well as an analysis of the product’s  
potential. 
 
3.1 Data Collection 
The following sections outline the specific details pertinent to the data collection process. 
This involved: conducting background research, interviews, and focus groups.    
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3.1.1 Background Research  
Performing the feasibility analysis required accumulating extensive background research. 
This research contributed to our assessment of the current state of the surgical tool industry. In 
addition, this research helped us decide which materials will compose the scalpel handle. Further 
research will help prepare us for existing competitors in the market.  
 
3.1.2 Patent Attorney 
In order to perform the analysis necessary to determine the market and product potential 
for 5G’s  ergonomic scalpel, we first needed to gather relevant data pertinent to intellectual 
property. Assessing the strength of the current patent of the scalpel required meeting with 
various patent attorneys to evaluate the perceived  protection  provided  by  5G’s scalpel patent. 
Since there are several patents issued regarding scalpels that differentiate from the existing 
scalpel, we needed to distinguish the similarities and differences between the existing scalpels 
and  5G’s prototype.  
 
3.1.3 Manufacturing  
To ascertain the projected costs associated with production of the 5G ergonomic scalpel, 
it was necessary to visit a manufacturing company. In addition to obtaining information on costs, 
we were able to gather valuable insight into the process and materials required to produce the 
product.  
3.1.4  Sterilization  
Meeting with a sterilization specialist at UMass enabled us to identify the cost associated 
with manufacturing the scalpel. Information provided by the specialist allowed us to identify 
sterilization options, as well as potential costs associated with the sterilization process.  
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3.1.5  Supply Chain Distribution 
To comprehend how hospitals order medical supplies, we interviewed a purchasing 
specialist at UMass. In doing this research we strived to gather information on how medical 
supplies are procured. This included understanding the manner, frequency, and logistics involved 
in the purchasing process. Discussions with a purchasing agent enabled us to approximate the 
costs necessary to manufacture the scalpel, as well as an acceptable price for the product. Not 
only was this information needed for our cost-benefit analysis, but it is also useful when 
identifying the optimal locations to manufacture the handle for 5G Medical.   
 
3.1.6 Consumer Research  
One of the most important methods we employed to collect data was conducting focus 
groups at hospitals. Through direct communication with practicing residents, as well as operating 
room nurses, we were able to obtain valuable feedback regarding their opinions on the traditional 
scalpel handle. Feedback from UMass residents helped us determine how likely they are to adopt 
this ergonomic scalpel. Additionally, we evaluated whether the 5G ergonomic scalpel provides 
enough benefits to surgeons in order to bypass the product inertia of the scalpel currently 
utilized.  
WPI requires Institutional Review Board (IRB) approval for data collection from human 
subjects. We needed to go through the IRB approval procedure in order to conduct the focus 
groups. This process involved filling out required paperwork and discussing potential risks 
before any data collection could be started. The Principal Investigator then reviewed the risks 
and benefits of the study, and approved the paperwork. We worked with Dr. Dunn to secure 
residents from UMass Medical to conduct our focus group with. Prior to our focus group 
discussion, we prepared a series of questions targeted at finding out further information on the 
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extent of daily scalpel use. The last portion of the focus group was a discussion on the potential 
benefits of the use of an ergonomic scalpel by surgeons.  
 
3.2 Feasibility Assessment  
After gathering a substantial amount of information pertaining to surgical device 
manufacturing, scalpels, and the 5G scalpel in particular, we began to assess of the feasibility of 
commercializing the ergonomic scalpel. We utilized this wealth of information and insight in 
order to systematically determine the feasibility of our project based on a multitude of aspects.  
The first aspect analyzed was the benefits the 5G scalpel provides over the similar 
products currently being utilized. We then weighed these benefits against the costs presented by 
the product in order to obtain a perceived net outcome. Once we determined whether the 5G 
scalpel’s  benefits  outweigh  its costs, we then proceeded to evaluate the risks associated with the 
product. After all of the potential risks of the commercialization of the product had been 
thoroughly elucidated, we compared them to the benefits defined by our cost-benefit analysis to 
conclude whether commercializing the product still appears feasible. If so, we will proceed to 
assess and establish the resources crucial to making the commercialization of the product a 
viable possibility, such as people and capital. If it appears that these resources are plausible for 
our cause to attain, then we must assess the current state of the market. In this assessment, the 
current state of the industry will be evaluated, as well as the key competitors, external drivers, 
and demand conditions. Figure 12 illustrates the commercialization cycle. The feasibility 
analysis section, in particular, is of extreme importance to our project. Potential new products 
can arise from a variety of sources, such as the ones listed on the left side of the figure. After 
having recognized this potential and evaluated all relevant factors, it is possible to determine 
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what the best course of action is in respects to commercialization. Several options are available, 
and it is important to note that abandoning the venture is always one of them.  
 
Figure 9: The Commercialization Cycle (Professor Schaufeld) 
 
3.3 Providing Recommendations  
Once we have gathered and thoroughly analyzed all of the criteria necessary in order to 
determine the feasibility of the 5G scalpel, the next step in the process is decision metrics. This 
step will require us to utilize our feasibility analysis in order to identify which approach to 
pursue for the commercialization of the product, if any. If it appears that this venture is a viable 
business opportunity, then we can begin to develop a project plan for the commercialization of 
the product. This plan would entail outlining the strengths and weaknesses of the 5G scalpel, 
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cost-benefit analysis, break-even analysis, production plan, as well as how to most effectively 
capitalize on these strengths to allow for the maximum potential of success. For instance, we 
may find that the scalpel is only feasible if we can attain the cost-reduction benefits of large-
scale production, or resources of another company. If this is the case, we would likely suggest 
5G form a joint venture or license the ergonomic scalpel to a competitor, rather than take on 
offering the product on their own. However, from our analysis we may conclude that this product 
is in fact not a viable business opportunity. If that is the case, we will provide 5G with a 
thorough, in-depth analysis of why we believe this product is not feasible. Additionally, we will 
provide 5G with numerous suggestions on how to improve on the feasibility aspects of the 
product in order to generate future success. By the end of this project we will be providing 5G a 
final report. In addition to the report, we will be meeting with our sponsor, Dr. Dunn, to present 
him with our findings and recommendations we have determined throughout the course of this 
project.  
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4 Results 
This chapter presents the results obtained after conducting our research. There are four main 
aspects that our project aims to assess: intellectual property, manufacturing, consumer research, 
and market.  
4.1 Intellectual Property 
Once the surgical device market has been thoroughly elucidated by conducting extensive 
research about the current state of the industry, the next step taken was to evaluate the perceived 
strength  of  5G’s  ergonomic  scalpel  patent.  An  accurate  assessment  of  the  patent’s  strength will 
enable us to determine the protection offered by this patent, and establish the room to operate 
within the industry. A patent that is evaluated and determined  to  be  a  “strong”  patent will 
provide much room to operate within the industry, and allow for a more aggressive marketing 
campaign.  However,  if  the  patent  is  deemed  as  “moderate”  or  “weak”  strength, the freedom of 
operation within the industry is severely reduced, due to lack of protection leading to possible 
substitute or knock-off products. Thus,  a  patent  perceived  as  “moderate”  to  “weak”  strength  
would likely entail a more specialized or niche market approach to advertising.  
 In order to ensure a lack of bias in the evaluation process of the patent, a third-party 
expert was brought in to examine and provide insight into the potential strength of the 5G 
ergonomic scalpel handle patent. The third-party patent expert that we were fortunate enough to 
meet with is Steve Carlson. Dr. Carlson is the president and CEO of OptoDot, a technology 
house corporation specializing in the development of high-technology equipment. He is a 
professional patent reviewer and writer, holding an excess of thirty patents in his name. 
Furthermore, Dr. Carlson is a registered legal patent witness, and has played a critical role in 
numerous high profile patent disputes.  
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 Upon meeting with Dr. Carlson, he was able to provide us with a plethora of insight, 
which proved vitally helpful in assessing the strength of the patent. Dr. Carlson insisted that in 
order to attain a solid grasp on the strength of a patent you must first look at Public PAIR on the 
U.S. Patent and Trademark Office (USPTO or PTO for short) for said patent, and then view the 
patent’s  history  under  the  Image  File  Wrapper.  The  USPTO  defines  a  patent’s  File  Wrapper as:  
"The folder into which papers for a particular application are collected and maintained. 
It contains a complete record of proceedings in the PTO from the filing of the initial 
patent application to the issued patent." (USPTO, 2014) 
 The value of this File Wrapper cannot be understated. Dr. Carlson and the USPTO iterate this 
point heavily, as can be seen in the following excerpt from the USPTO website: 
"…the  official  record  detailing  the  prosecution  of  a  patent  application  in  the  United 
States Patent and Trademark Office (PTO) is more than just a historical record. During 
the life of a patent, the prosecution record defines the scope of the claimed invention and 
the patent owner's rights." (USPTO, 2014) 
Upon review of the 5G scalpel patent’s  File  Wrapper,  Dr.  Carlson  ascertained  several  key  
elements vital to assessing the strength of 5G’s  patent.  First  and  foremost,  he  found  that  the  
patent had been reviewed and rejected once before for lack of uniqueness, due to broad claims 
conflicting with prior art. Although it is a common occurrence for a patent claim to be rejected 
following a first submission, it does have an impact on the perceived strength of the patent. Since 
Dr.  Dunn’s  original  U.S. filing on this product was rejected for possessing claims conflicting 
with prior art, it signifies that there are other similar products already patented, or even in the 
market. This fact hurts the perceived strength of the patent in question, allowing it less freedom 
to operate in the market due to the risk of potential substitute products from competitors.  
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 However, Dr. Carlson did point out that the patent was accepted on the second filing, and 
was  reviewed  by  the  same  individual  who  had  rejected  Dr.  Dunn’s  initial  filing.  Dr.  Carlson  
shared that the fact the reviewer of the patent was the same in both instances, and accepted the 
claim the second time, is positive with regards to the strength of the patent. Additionally, Dr. 
Carlson commended the second filing of this patents for possessing well-structured claims, 
stating that two strong independent claims, with a solid set of dependent claims branching off the 
two independent claims, speaks volumes to the strength of the patent.  
 Despite these several positive signs for the strength of the patent, Dr. Carlson ultimately 
concluded  that  5G’s  ergonomic  scalpel  handle  patent  is  of  “medium”  to  “mediocre”  strength.  Dr.  
Carlson  elaborated  on  the  factors  that  eventually  led  to  this  final  assessment  of  the  patent’s  
strength; concluding that, although there are several positive aspects associated with the second 
filing  of  the  patent,  “the  patent  reviewer  gave  him  (Dr.  Dunn)  all  he  was  going  to  get  in the 
second  filing”.  Therefore,  this  patent  is  of  mediocre  strength  because  it  will  not  allow  for  too  
much room to operate within the industry, due to the presence of comparable prior art.  
 Although  Dr.  Carlson’s  credentials  certainly  make  him  a  reputable  third-party source for 
the evaluation of this patent, we sought a second opinion in order to verify Dr. Carlson’s  
assessment of the patents strength. Therefore, we sought out the aid of an additional third-party 
source, which we were able to find in Steve Finch. Mr. Finch is a partner in a patent law firm 
called Finch and Mahoney, based out of Manchester, New Hampshire, making him an ideal 
consultant candidate for attaining a second opinion on the patent in question. After a brief phone 
conversation  with  Mr.  Finch,  it  was  abundantly  evident  that  Mr.  Finch’s  opinion  on  the  strength  
of  5G’s  scalpel  patent  concurred, and  validated,  Dr.  Carlson’s  assessment.  Both  parties  
accommodated the patent on the structure of the claims; however, both parties ultimately 
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concluded that the patent provided only minor protection and room to operate within the 
industry. 
 
4.2 Manufacturing 
4.2.1 Nypro 
In order to perform a thorough cost-benefit analysis, we needed to obtain information on 
medical device manufacturing costs. The team visited the Nypro manufacturing facility in 
Clinton, MA. We spoke with Mark Robichaud, Business Development Manager, who helped us 
understand the details of an injection molding process. There were three main themes that we 
were able to extract from our conversation with Mr. Robichaud: pricing, raw materials, and 
possible risks for the scalpel handle.  
Pricing 
Mr. Robichaud talked a lot about the pricing of the individual materials as well as the 
price of the completed device. Polycarbonate, the plastic used for the handle, runs about three 
dollars per pound. Elastomers, which would be used for the handle grip, run between six and 
seven dollars per pound. The molds used to produce the devices will cost about $20,000 for the 
front part and $15,000 for the back part. A completed device will cost between four and five 
dollars, and that is including overhead costs. We are looking at a minimum initial cost of 
$35,000 dollars just for the molds, meaning we will have to produce over 7,000 scalpels to make 
the investment worthwhile.  
Raw material 
As far as surgical devices go, the mold needed to complete the design of the scalpel, 
would be one consisting of one or two cavities because the volume does not indicate higher 
cavitation molds. ABS (Acrylonitrile Butadiene Styrene) is a good choice of material to craft the 
scalpel with; many medical products are made with ABS. ABS Plastic usually is medium in 
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strength. It is characterized as a resin with qualities similar to those of a standard resin and an 
engineering resin (www.absmaterial.com). This material is very tough and rigid, possessing a 
stable chemical resistance and high impact strength. Some of the limitations of material, 
however, are that it may have less than adequate weatherability and solvent resistance. Blends of 
Polycarbonate are about three dollars a pound. This blend is the cheapest resin that the company, 
Nypro, uses for medical parts. In order to make the weight of the scalpel greater, calcium 
carbonate could be added as filler. 
In order to mass-produce the scalpel with the tactile rubberized handle grip, a two-shot 
mold would be the way to do this. ABS is very compatible with TPE, and you can get it so that 
the parts will be able to physically bond. One could mold the sub straight part, then rotate the 
mold and inject over that in the elastomer portion. 
With two-shot molding, there are a couple of different ways in which the mold can be 
produced. If it were a four plus four model, where you mold four on the bottom sub straights on 
the bottom, you would inject one material, which forms the bottom, and subsequently rotate the 
mold up to another position. Then, another material will come in from the sides and over mold 
the second material. Therefore, every time the mold opens up, four parts come up, four sub 
straight parts rotate up, and as a result, there are four parts per shot. If it were a standard mold, 
there would be eight parts every time the mold opens up so only half the number of parts would 
be produced with the two shot mold. 
As far as temperature resistance in terms of sterilization, ABS and polycarbonates would 
be  compatible;;  they’re  both  high  temperature  resins.  The  melting  temperature  of  ABS  and  
polycarbonate is around 300 degrees Fahrenheit and steam is 212 degrees. These materials would 
also be able to be compatible with Ethylene Oxide sterilization, a common method used to 
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sterilize medical and pharmaceutical products this day in age. Polyether Imide (PEI) is a material 
that has high thermo-resistance and would be a material to consider using. It has high tensile 
strength, is resistant to flame, and is hydrolytically stable.  
Risk 
There were a few aspects about the scalpel handle that Mr. Robichaud mentioned which 
may be a concern for the future. Firstly, the weight of the handle will be the most important 
selling point for the surgeons. The surgeons will need to evaluate how the handle feels, meaning 
that the material of the mold and whether the mold is hollow or not will have a big effect on the 
feel of it. It will be a challenge to create something that the surgeons will feel total comfort in its 
application. In addition, this scalpel handle has no chance in competing in the regular scalpel 
market. This will be a custom high end device in order to have a chance or doing well in the 
market.  
 Another big concern that Mr. Robichaud mentioned was figuring out how the blade will 
fit into the non-disposable handle. Loading a blade in the handle will have to be simple so that 
the surgeons will be able to do it themselves and feel comfortable knowing that it will stay in 
there. The blade needs to be firmly fixed in the handle, or else the surgeons will not want to use 
an ergonomic handle if the blade itself cannot be guaranteed to stay in place.  
 
4.2.2 Sterilization  
We contacted the sterilization staff at the hospital to ask them a few questions about their 
sterilization process. Marlene Nintzel was able to answer a few of our questions about the 
hospitals sterilization process and give some ideas for improvements that could be made. 
Currently, the hospital sterilizes multiple units hourly, each containing a varying number of 
tools. The number of tools sterilized at one time depends on two factors: 
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- The size of the sterilization chamber  
- The method of packaging of the tool  
Depending on what type of sterilization technique the hospital is using and how many times they 
run a sterilization unit, the price can range from as low as $200 to well over $1000. The cost 
break down is shown in Table 1 below. 
 
The hospital is currently purchasing about 75% reusable and 25% disposable. Because 
75% of the surgical tools in the hospital are reusable, sterilization is a huge issue. Currently, the 
sterilization time for individual manufacturers differs from one to another; therefore, there is a 
high chance for mix-ups and incorrect sterilization to occur. Although most items require only 
four minutes of specific sterilization, some require times upward of twenty-five minutes. 
Recently, the FDA and AAMI (Association for the Advancement of Medical Instruments) are 
setting minimum requirements for manufacturers when it comes to sterilization. However, until 
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then hospitals must deal with different sterilization processes and time requirements.  Some 
examples of different sterilization techniques and times are listed below.  
-    Prevac Steam requires 270-273 degrees Fahrenheit exposure for not less than 4 minutes 
-    Pulse Vac Steam requires 270-275 degrees  Fahrenheit exposure for not less than 4 minutes 
-    Gravity Steam requires 270+ degrees Fahrenheit exposure for not less than 4 minutes 
-    Hydrogen Plasma (STERRAD) has a set cycle of 50 minutes with no cannulated or lumen 
items or implants 
-    Hydrogen Plasma (Sterrad NX) has a cycle of 28 minutes with no cannulated items or 
implants 
-    There is also Ethylene Oxide still used in some hospitals 
After one of these sterilization processes is used, each surgical tool is validated for cleaning, and 
then inspection and packaging occur. Although each tool is sterilized and placed in a sterilized 
package, there is a shelf life called terminal sterilization.   
 
4.2.3 Supply Chain Distribution 
To gain additional background information on the surgical tool supply chain, we 
interviewed Dr. Zinkus, who is currently the Director of Perioperative Business Operations. All 
orders and purchases placed go through Dr. Zinkus. All orders come in on an as needed basis and 
the supplies are managed by the nurses. Even though the supplies are mostly managed by the 
nurses, the surgeons have the most impact on what gets purchased. Nothing comes in on a 
standing order because supply is hard to predict especially in trauma cases. The supplies that are 
managed in the Operating Room have pars on them so that for example, if the nurses know that 
they need to have 50 of a certain tool and stock gets half empty, they know to reorder. Bulk 
orders are not ordered because of holding costs and the desire to use up most of the supply within 
a month time frame or less. Hospitals rarely order in bulk unless they get a really enticing deal or 
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discount and if they have room to store it. Most scalpels come sterilized and prepackaged, 
without an expiration date.  
Many hospitals order through distributors. UMass Medical specifically goes through 
Owens & Minor, a big distributor of medical supplies. The Materials Department at UMass 
orders supplies online from the distributors - this is the easiest way to place an order. Most 
distributors, like Owens & Minor will buy smaller disposable items in bulk and then hospitals 
like UMass will buy in smaller quantities from them. Dr. Zinkus recommended that 5G goes 
through direct suppliers instead of the distributors at first, in order to have the opportunity to gain 
some business.  
4.3 Consumer Research  
4.3.1 Focus Group 
For our consumer research we intended to interview eight to ten residents from UMass 
Memorial who had not been exposed to the scalpel prototype yet. However, when we arrived at 
the focus group it was composed of conference attendants, many of whom had seen or heard of 
the prototype previously. Only six of the invited residents came to the focus group. One of the 
residents had previously used the prototype to dissect a pig, while another had watched the 
prototype being test sterilized previously. During our interview, there were four main themes that 
the residents kept coming back to. These themes were:   
- The original scalpel 
- The limited use for the prototype 
- The existence of a tool that already fills the need  
- Problems with the existing prototype 
The residents did not see a problem with the scalpel they are currently using. Doctors have 
been  using  the  current  scalpel  for  centuries  and  it  hasn’t  been  a  problem  yet.  There  is  muscle  
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memory built into using the current scalpel, which has been accumulating over the years. This 
allows the residents to barely think about what they are doing when using the scalpel. One of the 
residents actually addressed the issue of bringing a new scalpel into the market saying,  
“…the only real use for this new scalpel is to make curved incisions…”  (male  subject  1). 
Another resident said that it may be hard to get people to switch over and use the prototype. 
[…because of] “tradition….we’ve  been  using  the  traditional  scalpel  since  the  1900s”  
(male subject 2).  
The residents also brought up the fact that there is already a scalpel that is used to make curved 
incisions, the beaver blade.  
After the first half of our discussion, we showed the residents the prototype and asked what 
they thought about it. During the interview, the residents described how the prototype would 
make it a lot easier to make curved incisions, but that this would be the only thing they would 
use it for. They asked many questions about the weight of the prototype because this is a huge 
factor for them. They need the prototype to weigh the same as the current scalpel so that their 
muscle memory is not affected. Another concern was that the prototype was a lot bigger than the 
current scalpel and it would block their view during some surgeries.  
Overall, the residents thought the current scalpel was working fine and that the proposed 
prototype would have to be marketed toward a very select group of surgeons, plastic surgeons. 
They did not see a reason to switch to a new scalpel unless that scalpel  
“had  all  the  benefits  of  the  traditional  scalpel  as  well  as  all  the  benefits  of  the  prototype”  
(male subject 2).  
 
4.3.2 Operating Room Nurses 
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The following data was collected from two separate interviews. This provides a summary of the 
information: 
We talked to nurses at UMass Memorial Hospital in Worcester, Massachusetts so we 
could gain some insight into how they go about arranging for surgery, particularly focusing on 
instrumentation set-up. We spoke with a female nurse from UMass, as well as a male traveling 
nurse working at UMass for several months, after having been to a multitude of hospitals across 
the United States as well as outside of the country. 
The amount of surgeries that a nurse will set up during their daily shift depends on the 
extent of the surgery. Sometimes, if it is an extensive procedure, they will set up for only one 
case. Their role when working the Operating Room is not only to prepare the room for surgery, 
but to prepare the patient, as well as to perform a count of the instruments. According to the male 
traveling nurse, certain instruments are typical for a standard set-up; however, every surgeon has 
preferences, which will tailor the final setup. 
The tools are already sterilized prior to surgery. The packaging has to be intact in order to 
ensure this. At UMass, in particular, light-tan colored tags indicate that sterilization has 
happened. Blades come in packages and are designed to slide on without the use of hands. In 
order to remove the blade, a needle driver is most commonly utilized to perform this action. 
Surgeons  use  one  scalpel  which  they  call  a  “number  3”.  It  is  a  metal  scalpel  and  is  the  
standard one that is used. It is reusable, made by Bard-Parker. It has been made by Bard-Parker 
for so long that, when asking the nurse for the instrument they need, some surgeons will refer to 
it  as  a  “Bard-Parker”.  Hospitals  are  trying  to reduce the use of disposable scalpels. Currently, 
they are used for quick slices. Disposable scalpels already have the blade attached, and those 
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blades are retractable for safety. Sometimes, nurses are asked to take out sutures; and, to quickly 
do this, they use a disposable scalpel. 
Depending on the surgery being performed and the preference of the surgeon, blades are 
chosen separately and then clicked into the metal handle. Once finished with the scalpel, it is 
thrown away into the sharps bucket. There are many different blades besides the standard blade. 
For example, different blades may be used for deep-tissue surgeries because surgeons do not 
want to risk transferring microbes from the skin into the wound. Some blades are even called hot 
blades because they are heated. 
In the opinion of the male traveling nurse, it would be a good idea if the scalpels were 
able to adjust sizes. He told us,  
“If ergonomics is your base, you have to look at the weight of the device, the angles. 70% 
of  surgery  is  exposure,  the  ability  to  access  that  specific  site.”   
Therefore, it is necessary that the shape and size of the ergonomic scalpel cater to this 
need. He told us that in his past experiences, he has had some hassles with trying to slide the 
blades into the scalpel handle. There tends to always be wear and tear around the part of the 
scalpel handle where the blade slides in. Therefore, it is necessary, when designing a new model, 
to pay close attention to this area so that there is a tight fit between the blade and handle and the 
blade does not break off. In designing a reusable blade versus a disposable blade, durability will 
be a primary concern.  
 
4.4 Market 
4.4.1 Cost-Benefit Analysis 
The first aspect to consider when generating a projected cost-benefit and break-even 
analysis is the fixed cost incurred when starting the new venture. From our discussions with 
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Nypro, we were able to determine that a 4-shot plastic injection molding machine would be 
required  in  order  to  create  5G’s  ergonomic  scalpel  handle  in  large-scale production. We can 
safely assume that the minimum cost for 4-shot injection mold needed to make this product to be 
about $25,000 for the front of the mold and $10,000 for the back portion, totaling an estimated 
$35,000 of initial investment for the equipment. However, these are the minimum projected cost 
numbers for the mold, as this product may require a specialty mold, which will only increase 
costs further. The fixed cost of the mold is certainly the most costly portion of the overhead for 
this product. For more detail, see Appendix A. 
Once the fixed costs of production have been thoroughly elucidated, the variable costs of 
the operation must be defined. The raw materials variable cost for this product appearsto be 
relatively cheap. It is anticipated that a polycarbonate plastic will be utilized as the plastic 
homopolymer comprising the majority of the handle. The cost of the polycarbonate raw material 
is roughly $5 a pound. Therefore, assuming that a pound of this material would constitute an 
estimated 20 scalpels, the projected variable cost of the polycarbonate material, per unit, is about 
$0.25. The second material utilized in the creation of this product is a thermoplastic elastomer 
(TPE) that will comprise the grip portion of the scalpel handle. The purpose of utilizing this 
material is the better quality it provides when compared to the polycarbonate used for the 
majority of the handle. Therefore, the costs of this material are slightly higher than that of the 
polycarbonate material used, at roughly $7 a pound. Thus, still assuming about 20 units produced 
per pound of material, the variable cost per unit for this material would total an estimated $0.35. 
An additional cost that must be factored into the variable cost to produce each unit is the cost of 
the blade. Although this may not be a direct cost for 5G, because they would likely not produce 
or purchase the blades themselves, it still is a relevant cost the consumer will incur on the final 
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product; and, therefore, must be factored into the projected costs. From our research and 
discussions with Mr. Zinkus, we were able to ascertain that the average cost of a common scalpel 
blade, when bought in bulk, is roughly $0.10 per unit. Consequently, the total variable cost of the 
raw materials totals a projected $0.70 per unit produced.  
Utilizing the numbers that we have attained through thorough research, we are able to 
generate a projected cost-benefit analysis for three potential marketing strategies: cost-reduction 
strategy, general strategy, and differentiation strategy. The overhead and R&D costs varied for 
each strategy depending on the perceived quality level of the product. For instance, the projected 
total variable cost, including raw materials and projected overhead and R&D cost for the general 
strategy, was an estimated $5.70 per unit, while the cost of the differentiation strategy increased 
to $7.70 per unit, with the cost reduction strategy reducing variable costs to a mere $3.70 per 
unit. The reason for the variation on these numbers is based on the assumption that the higher-
quality the product, the more it will cost to produce.  
These variable cost figures have a direct impact on the projected selling price of the 
scalpel for each strategy. Therefore, in order to determine an ideal price range, three different 
prices were tested for each strategy. Furthermore, the projected demand for the product was 
aggregated depending on the selling price for that particular scenario (e.g. the higher the price, 
the lower the demand, and vice versa).  
 First, we will look at the cost reduction strategy. For this strategy the estimated variable 
cost per unit of production is $3.70, and the three selling prices tested were $4, $5, and $6. The 
projected demand for the lowest-cost product, $4, was an estimated 3,000 units per quarter. This 
estimated demand dropped by 750 units each dollar increase in selling price. At the $6 price 
level, the time, in months, until break-even was the lowest of any price or strategy tested at a 
 
 
 56 
projected 30.43 months. However, from the research conducted, we do not believe this strategy 
to be a viable commercialization option moving forward. This is due to several distinct factors, 
the first of which being the amount of available customers in the area. According to US News, 
there are currently 1,022 surgeons practicing in Massachusetts. Additionally, from discussions 
with surgeons themselves, we were able to ascertain that this device would likely only be 
applicable to specialty surgeons, such as plastic surgeons. Thus, the target consumer population 
is reduced significantly. In order to achieve the projected demand for the scalpel priced at $6, or 
1500 units per quarter, 5G would need to secure virtually every potential customer in the New 
England area, or expand their operations to reach a larger market segment. Furthermore, since 
5G’s  ergonomic  scalpel  handle  is  reusable,  the  ability  to  generate  a  steady  demand  for  the  
product is exceedingly difficult and would require immediate expansion in order to find new 
customers and sustain demand. In conclusion, the cost reduction strategy is not ideal for a 
specialty product such as this (US News Health, 2014). 
 Next, we will thoroughly elucidate the general strategy projections.  For this strategy the 
three prices tested were $8, $10, and $12 per unit, generating a projected profit margin of 40%, 
75%, and 115% respectively. Much like the previous strategy, the demand for the product is a 
function of the selling price of said product. Thus, the demand for the $8 product is a projected 
1,000 units per quarter, with the quarterly demand decreasing by a factor of 300 units each 
additional $2 added to the selling price of the product. From these projections, the most efficient 
selling price, based off duration until break-even, would be $10 per unit. With consistent demand 
at $10 a unit, the projected time until break-even would be 34.88 months. However, much like 
the issue causing the cost-reduction strategy to not be a viable option, the demand required in 
order to make profit is likely unattainable in a small to moderately sized operation, due to the 
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fact that the scalpel is a one-time purchase because of its reusable capabilities. Therefore, 
generating sustainable demand, in order to make selling the product at this price level practical, 
would be extraordinarily difficult and likely not feasible.  
 Based on the research gathered, interviews conducted, and results attained from the 
previous strategies, it appears as though the differentiation strategy is the only potential viable 
option for 5G at this point in time. For such a specialty product, which is likely only a one-time 
purchase due to its reusability, the profit margin per product becomes vital. From our discussions 
with Mr. Zinkus, Purchasing Director at UMass Memorial Medical Center, we were able to 
determine that the average selling price of most high-quality reusable scalpels, when bought in 
quantities of 5 or more, to be around $20. Therefore, the three selling prices tested for this 
strategy were $20, $25, and $30. The projected quarterly demand for the scalpel priced at $20 is 
200 units, with the demand decreasing at an estimated 50 units for every $5 increase in selling 
price. We perceive this to be a more realistic demand than the previous two strategies. However, 
since the demand is relatively low, due to it being such a highly specialized product, the profit 
margin generated per unit sold is a crucial statistic. For the $20 scalpel, the profit margin per unit 
is a projected 160%, increasing to 225% and 290% for the $25 and $30 selling prices, 
respectively. From these projections, we were able to conclude that the optimal selling price for 
the scalpel, utilizing a differentiation strategy, would be about $25. Selling the scalpel at $25 per 
unit, when purchased in quantities of at least five units, would take 40.46 months to recoup the 
initial investment, assuming demand remains consistent. If demand does not remain consistent 
however, due to the reusable nature of the product, then the time required to break-even could 
increase significantly. This price remains consistent with the information provided to us by Mr. 
Zinkus, stating that the largest increase in price a hospital will be able to sustain over the current 
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cost of specialty scalpel purchases, roughly $20 per unit on average, would be a $5 increase. 
Although, Mr. Zinkus did specify that the cost expansion would only occur if the product were 
heavily demanded by the surgeons themselves. In conclusion, based on of our projections, the 
ideal  selling  price  for  5G’s  ergonomic  scalpel  handle,  if  commercialized,  would  be  roughly  $25  
per unit.  
  
5 Discussion and Recommendations 
Chapter 5 encapsulates our  final  decision  on  the  perceived  feasibility  of  5G’s  ergonomic  
scalpel, as well as a thorough explanation of the analysis that this decision derived from. 
Additionally,  based  off  our  assessment  of  the  product’s  feasibility,  we  will  provide  5G  with  
possible strategies and alternative methods for commercialization of their ergonomic scalpel 
handle.  
 
5.1 Discussion 
Based on the rigorous research conducted, and the resulting data and insights collected, as 
discussed in chapter 4, we were able to reach a final verdict  on  the  perceived  feasibility  of  5G’s  
ergonomic scalpel handle. Ultimately, we concluded that this product would not be a viable 
option for commercialization as a stand-alone product. However, this is not to say that the 
product concept should be abandoned entirely; rather, alternative methods to commercialization 
may be required in order to generate future success if this product reaches market. Several key 
aspects, found in our research, contributed the process of determining that this product would not 
thrive in the market as a stand-alone product. We isolated these key aspects, which ultimately led 
to our final assessment, into several distinct segments: the current marketplace, intellectual 
property, end-users, and financials. 
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 Determining the need felt by the market for change and innovation is a crucial step when 
assessing a product’s feasibility. In order to achieve this assessment, the current state of the 
marketplace must first be evaluated. The research gathered pertaining to the medical and surgical 
device industries in the early portions of our project, as can be seen in-depth in chapter 2, 
enabled our group to determine that the current state of the market does not present a need for 
this new product. This conclusion was ascertained due to the recent, and continued, success of 
the industry as a whole. The success seen was generated despite employing the same basic 
scalpel design for the past several decades. Therefore, although the market itself is prospering, 
which may have positive implications, it does not appear that the need for a new product is 
present.  
 Although the current state of the market does not call for change, this fact alone is simply 
not  enough  to  deem  5G’s  scalpel  not  a  viable  option  for  commercialization.  Next,  we  must  
determine the protection and freedom of operation provided by the intellectual property 
possessed by the product. From our discussions with several patent experts, we were able to 
determine  that  the  patent  is  of  “moderate”  to  “weak”  strength.  Therefore,  the patent does not 
provide the luxury of exemplary protection when the product reaches market. Consequently, this 
entails a more conservative marketing scheme for the product, due to the fear of imitation 
products and competing on costs with much larger competitors if targeted at the general market. 
Thus,  the  moderate  to  weak  characteristics  of  the  patent  require  changing  5G’s  marketing  focus  
from a generalized market, to more specialty and niche marketplaces. Although this assessment 
has negative implications on the feasibility of the product, because the potential market size has 
been vastly reduced, it does not constitute this product being a non-viable option for 
commercialization.  
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 Due to the negative implications provided by the two previous segments analyzed above, 
there must be a distinct need felt from the end-user, surgeons, in order to help justify the validity 
of  bringing  5G’s  ergonomic  scalpel  handle  to  market.  Prior  to  assessing  the  end-user’s  opinions  
on the product in question, we must first determine if there is a need for change from the 
products currently utilized. From our discussions with hospital personnel we discovered that they 
found only minor, if any, shortcomings with the current scalpel. Thus, the need for change and 
introduction of a new product is not clear. Furthermore, not only is the need for change not 
evident, rather the fear of change supersedes the desire for change. The fear of change is derived 
from the comfort level felt with their current scalpel, and the concern that the learning curve 
associated with a new product will negatively impact their surgical performance. As one of the 
male surgeons we interviewed put it: 
“…for  surgeons  it’s  all  about  muscle  memory…I’ve  grown  so  accustomed  to  my  current  
scalpel that I can make an incision, with the appropriate amount of force applied, with my 
eyes  closed.”  
Although this is almost surely a hyperbole, the message behind the statement is critical. The 
reason that there has been virtually no innovation in this product category over the past several 
decades is due to the fact that there is simply no need for change. Furthermore, that the risks 
associated with change in this industry far outweigh the potential benefits any form of change 
may provide. Once again, this aspect has a negative  effect  on  the  perceived  feasibility  of  5G’s  
scalpel handle, as it reduces the estimated demand for the product substantially.  
 Once this conclusion about the need for change from the currently utilized products had 
been drawn, we were able to discuss  their  opinions  on  5G’s  prototype  scalpel.  Despite our 
subjects having been exposed to the prototype previously and their close working relationship 
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with  the  project’s  sponsor,  we  were  able  to  extract  several important insights from our focus 
group. First and foremost, it was iterated that  this  product’s  primary  usage  would  be  for  circular,  
surface  incisions.  This  is  due  to  the  bulkiness  of  the  prototype  inhibiting  the  surgeons’  ability  to  
use it inside a patient after the initial incision. Therefore, the subjects believe that this product 
would only be utilized by specialized surgeons, such as plastic surgeons, for only a handful of 
procedures. However, we were informed that there is already a specialty scalpel and blade for 
incisions of this type in use. This fact alone drastically reduces the perceived market size and 
estimated  demand  for  5G’s  ergonomic  scalpel  handle.  A  final  bit  of  useful  information  that  can  
be extracted from the focus group, that furthers the negative impact on the estimated demand, is 
the lifecycle of their current scalpel. We were astonished to discover that the reusable metal 
scalpels the surgeons presently use date back as far as forty or more years. This fact implies that 
the hospital does not currently expend much capital on the purchase of reusable scalpels, and that 
it is virtually a one-time  purchase.  Thus,  the  initial  demand  for  5G’s  product  will  have  difficulty  
remaining sustainable over-time without continued expansion of market reach.  
 Each of the various aspects of feasibility, elucidated above, has a significant impact on 
the  financial  projections  for  5G’s  ergonomic  scalpel  handle.  Therefore,  the  negative  implications  
drawn  from  each  aspect,  in  the  process  of  assessing  the  product’s  feasibility,  will  have  an  
adverse effect  on  the  profit  potential  for  5G’s  new  scalpel.  In  order  to  determine  the  remaining  
profit potential for this product, a cost-benefit and break-even analysis were performed, for more 
detail refer to chapter 4 or the appendix for charts and tables of the projected financials. From 
our assessment, we concluded that the only potentially plausible pricing strategy would be the 
differentiation plan, due to the need for focusing on niche and specialty markets. From our 
discussions with Mr. Zinkus, the purchasing agent for UMass Memorial Hospital, we were able 
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to ascertain that the current specialty scalpels purchased cost roughly $20, on average. 
Furthermore, Mr. Zinkus notified us that the threshold for additional cost they would be willing 
to spend on a scalpel, if the surgeons demanded it, would be about $5 maximum per unit. 
Therefore, the price-level for the differentiation plan of $30 per unit would likely not be a 
feasible selling price for this product. Thus, the only potentially viable selling prices for 5G’s  
product would be between $20 and $25, from which we were able to determine that optimal 
price-level would be roughly $25. At this price, assuming accurate assumptions and consistent 
demand, it would take over 2,000 units, or just over 40 months, to recoup the initial investment 
costs of the mold required. However, due to small-scale  size  of  5G’s  operation,  it  is  irrational  to  
believe that a demand that great could possibly be met because the target population, specialty 
surgeons, is far less than half the required demand to recoup the fixed costs if the entire target 
population utilizes this product. Furthermore, in order to generate any form of sustainable 
revenue over time, 5G’s  market  reach  and  operation  size  would  need  to  expand  continuously  to  
simply keep demand consistent. In conclusion, from a financial perspective this venture appears 
to offer little upside. The negative implications drawn from the financial aspects of the product, 
coupled with those from the other vital aspects discussed, appear  to  signify  that  5G’s  ergonomic  
scalpel handle is simply not a viable option for commercialization as a stand-alone product at the 
moment.  
 
5.2 Recommendations  
Despite  arriving  at  the  conclusion  that  5G’s  ergonomic  scalpel  handle  would  not  be  
feasible for commercialization as a stand-alone product currently, that is not to say that there is 
not profit potential in this product. However, as it stands currently, alternative methods may need 
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to be employed in order to quell some of the primary issues resulting in the products 
unfeasibility. In this section, we will explore and offer suggestions 5G might incorporate in order 
to salvage this product in the most effective manner possible. We will discuss a variety of 
alternative strategies 5G might consider for this product, such as: attacking niche markets 
unrelated to the surgical field, licensing the product to a large-scale and established company, 
and utilizing this concept as a platform product to generate a family of ergonomic surgical 
devices. 
It  appears  that  one  of  the  most  prevalent  issues  limiting  the  ergonomic  scalpel’s  
commercialization potential is the limited size of the target market segment: specialty surgeons. 
A possible alternative method 5G could employ is to expand their target segment to various other 
niche market segments, such as the hobbyist market. Although capturing demand from the 
hobbyist market alone would almost surely not be enough for this product to thrive, coupled with 
the initial target segment of specialty surgeons, it could help 5G expand their target market size 
and resolve some of the issues of sustainable demand. Additionally, the hobbyist market is 
merely one example of potential alternative markets 5G could explore with this scalpel product. 
Other possibilities could range from veterinarians to lab technicians.  
It has become apparent, from the conclusions derived in the previous section, that one of 
the  persistent  issues  hindering  5G’s  ergonomic  scalpel  from  being  considered  feasible  are  the  
massive overhead and fixed costs incurred. One potential remedy for this obstacle would be 
licensing this product to a much larger, and more established, company, such as X-Acto. This 
would enable 5G to virtually negate any costs not associated with R&D, while generating a 
steady stream of revenue if the product proves successful. Furthermore, licensing may also help 
quell some of the sustainable demand issues caused by limited market size and reach. A 
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prominent company in a similar field, such as X-Acto, would have established demand in a wide 
array of locations that 5G might otherwise not have access to. 
Our  final  suggestion  for  an  alternative  method  to  commercialization  of  5G’s  ergonomic  
scalpel handle, is to utilize this product as a platform product and create a family of ergonomic 
surgical tools. Theoretically, this would enable 5G to expand their market potential by delving 
into various other target segments, aside from strictly specialty surgeons. Furthermore, 
introducing a line of ergonomic surgical tools may help suppress  some  of  the  surgeons’  fear  of  
change by incorporating a similar product concept in various other aspects of their work. 
Additionally, the hospital purchasing staff, as well as potential investors, may be more inclined 
to invest in a bundle of new products, as oppose to an individual new product. The suggestions 
elucidated above are merely a few potential avenues for alternative methods to 
commercialization, derived from several brainstorming sessions, that 5G may wish to 
incorporate to heighten the commercial feasibility of their ergonomic scalpel handle if brought to 
market. 
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In conclusion, we assessed four areas of the potential prototype: intellectual property, 
manufacturing, consumer research, and the market. After analyzing each area, we found that all 
four had marginal potential. This led us to recognize three potential possibilities for the proposed 
prototype. These three possibilities are hobbyist, licensing, and a family of ergonomic surgical 
tools.    
Hobbyist  
Market   
Licensing   
Family  of  
Ergonomic  
Surgical  Tools 
Other 
Market 
Consumer  
Research 
Intellectual 
Property 
Manufacturing 
Marginal 
ASSESSMENT 
Marginal 
Marginal 
Marginal 
Figure 10: Potential Markets 
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5.3 Post-Presentation Considerations 
5.3.1 Product Champion 
After presenting the results of our findings to our sponsor, Dr. Dunn, he noticed that we 
quantified four distinct factors contributing to our ultimate determination of the perceived 
feasibility  of  5G’s  ergonomic  scalpel  handle;;  the  market, consumer research, intellectual 
property, and manufacturing. Although Dr. Dunn agreed with the conclusions drawn from each 
of these four various feasibility aspects, from an objective perspective, he offered an intriguing 
inquiry for our group to consider  moving  forward;;  “How  can  you  quantify  the  impact,  both  
positive  and  negative,  of  a  product  champion  on  the  potential  success  of  a  given  product?” 
              Product champions can be a vital component when introducing a new product 
innovation to the market. A product champion is typically a senior level individual, or executive, 
who acts as an advocate for the product and encourages further internal development and 
external promotion of a product. Often times this is the inventor. Virtually, all successful 
innovations, particularly radical innovations, require the constant support and knowledge 
provided by a product champion. However, where difficultly arises is in distinguishing whether 
the strong support and promotion provided by a product champion is warranted, and therefore 
beneficial,  or  if  the  product  champion’s  emotional  investment  in  their  product  hinders  pragmatic  
decision making. 
              Although it is virtually impossible to accurately predict the role a product champion will 
play in the ultimate success, or failure, of a product from the onset, the benefits of a strong 
product champion can be seen more so in certain industries over others. For instance; the 
presence of a strong product champion for a radical innovation will present augmented value in a 
traditional, or conservative, industry hesitant to adopt change, such as the surgical device 
industry. Although the role, and impact, of a product champion can vary greatly from product to 
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product and is difficult to quantify, the fact remains that a product champion can play a 
significant role in the commercialization feasibility, and potential for success, of any new 
product.  
5.3.2 Funding Options 
After presenting our findings to our sponsor, he requested we inquire about potential 
funding for 5G. Some forms of funding we suggest 5G look into if moving forward with the 
prototype are: grants from the small business technology transfer (STTR), the National Institutes 
of Health (NIH), or the National Science Foundation (NSF), angel investors, or venture 
capitalists. These various sources of funding may allow 5G to obtain enough capital to cover the 
initial investments needed to purchase the four shot injection molding as well as all other costs 
associated with starting production.  
Grants are one option that 5G could potentially use for funding. In order to receive a 
grant you must submit an application, which will be reviewed by a minimum of three experts in 
the fields represented by your proposal. During the review process, each proposal is scrutinized 
for its potential technological and commercialization capabilities. Small business grants are a 
smart option because the government does not charge interest, nor does it demand control of 
your business in return. Although these are viable options for funding, grants are in high demand 
and are very competitive. Consequently, other forms of funding should be considered.   
STTR,is another  funding  opportunity.  This  program  is  dedicated  to  “supporting scientific 
excellence and technological innovation through the investment of Federal research funds in 
critical  American  priorities  to  build  a  strong  national  economy”  ("Small  business  innovation," 
2014). The program is split into three phases each of which would provide stability for 5G as it 
progresses through the research and development stages. The three phases are listed below: 
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x Phase I: $100,000 maximum for 1 year - establish the technical merit, feasibility, and 
commercial potential of the proposed R/R&D efforts and to determine the quality of 
performance of the small businesses 
x Phase II: $750,000 maximum for 2 years - continue the R/R&D efforts 
x Phase III: Not funded – business pursues commercialization objectives resulting from 
the Phase I/II R/R&D activities 
The NIH is another possible funding option. The process to become approved takes 
almost a year. The first three months are the receipt and referral time period. During this time, 
reviewers are assigned to look at the applications for validity. The next four months are 
dedicated to peer review and scoring of each application. The last two months involve grant 
awarding and negotiations. Since a new scalpel is a medical improvement, 5G would qualify to 
enter an application to NIH to be evaluated.  
Additionally, the NSF is an agency that provides funding for early stage research and 
development at small businesses. As stated on the website, the  R&D  funded  by  NSF  should  “be  
based on transformational technology with high technical risk and potential for significant 
societal  or  commercial  impact”  (NSF, 2014). The grants provided by the NSF are split into 
phases: 
x Phase I: $150k over 6 months - Feasibility Study 
x Phase II: $750k over 2 years - Development Project 
When it comes to venture capital funding, it is suggested you exhaust all other options of 
funding before looking into this avenue. This is because venture capitalists take a large portion of 
your company, in equity and control, when they give you funding. Therefore, you should not use 
venture capital funding unless you require amounts greater than one million dollars.  
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Angel investors are another form of funding that 5G could potentially use. Angel 
networks usually provide between $25,000  and  $250,000,  which  is  in  the  range  of  5G’s  needs.  In  
order to obtain angel investment, you must network extensively to find an investor that 
understands and is interested in your industry. This is important because the angel investor will 
be involved in your business and needs to understand where you are trying to take your company 
and share your views.  
5.3.3 Interview with Independent Medical Device Sales Representatives 
As requested as a follow-up analysis, after presenting to our sponsor, we interviewed two 
independent medical sales representatives in order to gain insight into medical equipment sales. 
The two representatives have dealt with representing innovative products similar to the 
ergonomic scalpel handle, throughout the duration of their careers. Both have had nearly 20 
years of sales experience, including working for large companies in various sales roles, and as an 
independent sales representative. As one representative told us, he represents products that are 
just coming into market. He shows the product to physicians, hospitals, or whoever the target is; 
supporting the product along the way. He watches surgeries with the surgeons and gets involved 
with the hospital administration in purchasing the product. 
In choosing a product to potentially represent, both representatives said they attend trade 
shows, and make rounds, looking at the various booths to see if there are particular products that 
best fit with what they feel comfortable selling. Both sales representatives also secure clients via 
referrals from people  they’ve  developed  strong  relationships  with  over  the  years.  Both  
emphasized the importance of developing and maintaining relationships with physicians such as 
our sponsor Dr. Ray Dunn, when working in the medical sales industry, because they possess 
valuable first-hand knowledge about how the people and tools function in the medical field. 
Some of their sales relationships have been maintained for as long as fourteen years.  
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If a particular product interests them, they will also be more inclined to take on selling it. 
Also,  if  they  can  obtain  a  product  with  some  existing  business,  they’ll  be  more  inclined  to  take  it  
on because they know that if someone else can sell it, then they can sell it. Typically these 
medical device representatives carry with them, a range of four to six products on average in 
their  daily  bags  at  one  time.  They  do  this  so  that  not  “all  their  eggs  are in  one  basket.”  These 
representatives are currently working as independents and entirely depend on actual sales for 
income. Finally, in discussing whether these sales representatives had ever worked with doctors 
who have invented a device themselves, they expressed to us that physicians in fact developed 
the majority of devices they have sold. They train with the physicians to learn about the product, 
and to see it and the process behind it.  
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through steam sterilization. This process does not take too much time and is done in an 
autoclave. This article will help our project because the sterilization process will be 
something that 5G will need to be familiar with before it goes into the market. 
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The USPTO is the most prominent database for attaining and reviewing patents valid in 
the United States. Thousands of new patents are filed yearly through the USPTO. This is 
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an important resource to our project because it allows us to assess the strength of the 
patent in question, as well as find and prior art that appears to be similar  to  5G’s  patent.   
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